上海交通大学学报（医学版）

›› 2009, Vol. 29 ›› Issue (8): 939-.

• 论著（临床研究） • 上一篇    下一篇

焦虑障碍患者血浆脑源性神经营养因子水平的研究

王 媛, 肖泽萍, 林治光, 李 樱, 任娟娟, 李春波   

  1. 上海交通大学 医学院精神卫生中心生物化学研究室, 上海 200030
  • 出版日期:2009-08-25 发布日期:2009-09-27
  • 通讯作者: 肖泽萍, 电子信箱: xiaozeping@gmail.com。
  • 作者简介:王媛（1983—）, 女, 硕士生；电子信箱: wangyuan129@163.com。
  • 基金资助:

    上海市市级医院新兴前沿技术联合攻关项目（SHDC 12006105）; 国家高技术研究发展计划（“八六三”计划）（2007AA02Z420）; 上海市科委重点科技攻关项目（074119520）; 上海市优秀学科带头人计划（08XD14036）

Analysis of plasma brain-derived neurotrophic factor levels in patients with anxiety disorders

WANG Yuan, XIAO Ze-ping, LIN Zhi-guang, LI Ying, REN Juan-juan, LI Chun-bo   

  1. Department of Biochemistry Research, Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai 200030, China
  • Online:2009-08-25 Published:2009-09-27
  • Supported by:

    Joint Key Project of New Frontier Technology in Shanghai Municipal Hospitals, SHDC 12006105; National High Technology Research and Development Program of China, “863”Program, 2007AA02Z420; Shanghai Science and Technology Committee Foundation, 074119520; Program for Shanghai Outstanding Academic Leader, 08XD14036

PDF (PC)

1590

摘要：

目的 探讨焦虑障碍患者血浆脑源性神经营养因子（BDNF）水平的特点。 方法 收集广泛性焦虑症（GAD）患者104例，强迫症（OCD）患者114例，社交焦虑症（SAD）患者37例及63名正常对照者，其中GAD、OCD和SAD组内按入组时药物使用情况各分为两个亚组：A组为从未使用过任何精神科药物者或经过药物清洗1周及以上者；B组为入组时正在进行药物治疗者。采用汉密尔顿焦虑量表（HAMA）/耶鲁-布朗强迫量表（Y-BOCS）/交往焦虑量表（IAS）和状态-特质焦虑问卷（STAI）进行评分；采用ELISA法测定血浆BDNF的质量浓度；并对其中18例患者于药物治疗10周后复测各量表及血浆BDNF的质量浓度。 结果 ①各病例组血浆BDNF质量浓度均低于正常对照组，差异有统计学意义（P<0.001），但病例组间两两比较差异无统计学意义（P>0.05）。②各病例组内A、B亚组间血浆BDNF质量浓度差异均无统计学意义（P>0.05）。③年龄、性别对各组血浆BDNF质量浓度均无统计学意义的影响（P>0.05）；各病例组患者血浆BDNF质量浓度与疾病的严重程度、焦虑状态评分、病程的关联程度均无统计学意义（P>0.05）。④18例患者经药物治疗10周后，血浆BDNF质量浓度变化无统计学意义（P>0.05）。结论 血浆BDNF的水平可能为焦虑障碍疾病状态的生物学标志之一。

关键词: 广泛性焦虑, 强迫症, 社交焦虑症, 脑源性神经营养因子, 血浆

Abstract:

Objective To explore the characteristics of plasma brain-derived neurotrophic factor (BDNF) levels in patients with anxiety disorders. Methods One hundred and four patients with generalized anxiety disorder (GAD), 114 patients with obsessive-compulsive disorder (OCD), 37 patients with social anxiety disorder (SAD) and 63 normal controls were enrolled, and patients in GAD, OCD and SAD groups were divided into two subgroups, respectively (subgroup A: those with no history of antipsychotic drug use or those with drug washout for more than 1 week; subgroup B: those with drug treatment at enrollment). Assessment was performed with Hamilton Anxiety Scale (HAMA)/Yale-Brown Obsessive-Compulsive Severity Scale (Y-BOCS)/Interaction Anxiousness Scale (IAS) and State-Trait Anxiety Inventory (STAI), and plasma BDNF levels were detected by ELISA. Eighteen patients with drug treatment were performed a second scale assessment and detection of plasma BDNF levels 10 weeks later. Results ①The plasma BDNF levels in each patient group were significantly lower than that in normal control group (P<0.001), while there was no significant difference among three patient groups（P>0.05）. ②There was no significant difference in plasma BDNF levels between subgroup A and subgroup B of GAD, OCD and SAD groups (P>0.05). ③Age and sex did not significantly influence BDNF plasma levels in each group (P>0.05). Disease severity, state anxiety inventory (SAI) score and disease course were not relative factors with BDNF plasma levels in GAD, OCD and SAD groups (P>0.05). ④The BDNF plasma levels did not change significantly in the 18 patients with drug treatment for 10 weeks (P>0.05). Conclusion Plasma BDNF level may be a useful biomarker for the state of anxiety disorders.

Key words: generalized anxiety disorder, obsessive-compulsive disorder, social anxiety disorder, brain-derived neurotrophic factor, plasma

中图分类号: